In the process of exploring the excavation and application of marine bioactive substances, mu-conotoxin, as a small molecule peptide derived from the venom of marine cone snails, has successfully broken through the application limitations of natural toxins through its unique molecular conformation and targeting activity. It has opened up a new development path in the two core fields of medical beauty and skin care and drug research and development, becoming a new type of bioactive substance with practical value, innovative potential, and market prospects.
The application value of such synthetic derivatives can be fully released, relying not only on the precise optimization and modification of their molecular structure by modern biosynthetic technology, removing toxic fragments from natural toxins and retaining core active sites, but also on the diverse exploration and deep analysis of their efficacy and targets by researchers, laying a solid foundation for their scenario based applications. The following will focus on the two core application directions of medical beauty, skincare, and drug research and development, and provide a more detailed analysis and explanation based on their molecular characteristics and application advantages.
Products Overview
Mu-conotoxin COA
 |
||
| Certificate of Analysis | ||
| Compound name | Mu-conotoxin | |
| Grade | Pharmaceutical grade | |
| CAS No. | 936616-33-0 | |
| Quantity | 33g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090066 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.54% |
| Loss on drying | ≤1.0% | 0.42% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.98% |
| Single impurity | <0.8% | 0.52% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage |
Store in a sealed, dark, and dry place, 2-8°C |
|
|
|
||
Application characteristics of this peptide synthetic derivative in the field of medical beauty and skincare
The artificially synthesized derivative of Mu cotoxin has become a new favorite of anti wrinkle active ingredients in the field of medical beauty and skincare. Its core advantage lies in the precise improvement of skin dynamic lines and the gentle regulation of facial skin state. With the molecular design of biomimetic synthesis, it achieves a dual improvement of anti wrinkle efficacy and skin adaptability. The specific characteristics can be developed from the following dimensions:
Optimization characteristics of biomimetic synthesis technology.
The extraction difficulty and low yield of natural μ - cotoxin make it difficult to meet the large-scale application in the field of skincare. The breakthrough of artificial biomimetic synthesis technology has solved this pain point.
By accurately replicating the core conformation of natural peptide chains and optimizing the arrangement and combination of amino acid residues, synthetic derivatives retain the active core of the original molecule while removing toxic fragments from natural toxins, reducing the risk of skin irritation.
The synthesis process can achieve precise purity control, with most derivatives having a purity of over 98%, providing a safety guarantee for skincare applications.
The dual effect of soothing facial muscles and improving wrinkles.
Synthetic derivatives can gently regulate facial nerve conduction, alleviate excessive contraction of facial muscles, and fundamentally reduce the generation and deepening of dynamic lines, especially for expression driven grooves such as forehead wrinkles and crow's feet, showing significant improvement effects.
Compared with traditional anti wrinkle ingredients, its effect is more targeted, penetrating the epidermal layer directly to the deep layers of the skin, and fitting the action site of the facial muscles.
It can achieve rapid effect, usually observed to soothe the wrinkles within 2 hours after application, while avoiding facial stiffness and maintaining the natural state of the skin.
Diversified scenarios for product adaptation.
The molecular stability of these derivatives is strong. The folded structure formed by three pairs of disulfide bonds makes them not easy to be degraded by skin enzymes, and can be adapted to a variety of skin care formula systems.
Whether it is water-based essence, lotion or face cream, it can maintain good activity. At the same time, its penetration performance can be further improved through formula optimization.
Paired with cationic penetrants, it can significantly increase skin deposition and is suitable for different skin types, especially for those with dynamic wrinkles caused by rich facial expressions. It has dual effects of anti wrinkle and skin conditioning.
Kazuki Sato Research on Toxicology: Research on Imidaconazole [J]. Department of Chemistry, Tongren Institute of Chemistry, 2002
Hangzhou Chuangti Biotechnology Co., Ltd The youthful password for celebrities: conotoxin [J]. Research on Cosmetics Raw Materials, 2024 (5): 18-25
Exploring its potential value in the field of drug development
As a highly promising lead compound, mu-conotoxin has demonstrated unique advantages in the development of muscle relaxants, analgesics, and local anesthetics.
Its high molecular specificity and adjustable activity provide a new template for the development of new drugs, which is expected to break through the limitations of traditional drugs.
The specific potential value can be analyzed from 3 directions:
01.The leading potential of muscle relaxants.
The synthetic derivatives of μ - conotoxin can achieve mild and efficient muscle relaxation by precisely regulating the contraction signal of muscle fibers. Compared with traditional muscle relaxants, its target is more selective, reducing the widespread inhibition of muscles throughout the body and lowering the risk of adverse drug reactions. At present, the relevant research and development has entered the early exploration stage.
Through molecular structure modification, the onset speed and duration of muscle relaxation can be further optimized, which is expected to be applied in surgical assisted muscle relaxation, muscle spasm relief and other scenarios, providing new options for clinical muscle relaxation treatment.
02.The innovative direction of analgesic drugs.
Traditional analgesic drugs often have drawbacks such as addiction and tolerance, while μ - conotoxin derivatives, with their unique analgesic mechanism, can selectively block the transmission of pain signals and are less prone to addiction, providing important ideas for the development of new non addictive analgesics.
Existing research has shown that some derivatives exhibit significant analgesic activity in animal experiments. Through further structural optimization and clinical exploration, they are expected to be applied in scenarios such as chronic pain and postoperative pain, filling the market gap of non addictive analgesic drugs.
03.The research and development potential of local anesthetic drugs.
The derivative of mu-conotoxin can achieve precise local anesthesia by inhibiting local nerve conduction. Its range of action is controllable, the effect is rapid, and it has lower irritation to local tissues. Compared with traditional local anesthetics, it is more suitable for small surgeries, local diagnosis and treatment, and other scenarios.
At present, relevant research and development focus on optimizing its anesthesia duration and bioavailability, enhancing its local retention through molecular modification, reducing drug metabolism speed, and potentially developing efficient and safe new local anesthetic drugs to improve the clinical experience of local anesthesia diagnosis and treatment.
The sources of information cited above are:
Li Ruihan, Wang Dan In Silico Conotoxin Studies: Progress and Prospects[J]. PMC, 2024, 11677113.
X technology R&D team Preparation method of μ - type conotoxin peptide and its pharmaceutical composition and application [P]. Chinese patent: 20241189875.2, 2025
In summary, the artificially synthesized derivatives of Mu cotoxin have achieved innovative breakthroughs in anti wrinkle efficacy in the field of medical beauty and skincare with the precise empowerment of modern biosynthetic technology. They completely break the limitations of traditional anti wrinkle ingredients, such as slow onset, easy stiffness, and poor adaptability.
With the core advantages of mild control and targeted action, they provide efficient and safe solutions for improving various expression driven dynamic patterns, meeting consumers' demand for natural anti wrinkle and promoting the iterative upgrading of active ingredients in the field of medical beauty and skincare.
In the field of drug development, μ - conotoxin, as a highly promising lead compound, has injected new impetus into the innovative research and development of muscle relaxants, analgesics, and local anesthetics due to its modifiable molecular structure and high specificity of its target.
It is expected to break through the bottlenecks of traditional drugs in terms of adverse reactions, addiction, and limited effects, and provide a safer and more effective new choice for clinical diagnosis and treatment.
With the continuous deepening of molecular synthesis technology, structural modification technology, and application research, the application boundaries of mu-conotoxin and its derivatives will continue to expand.
Its application scenarios in the fields of medical beauty, skincare, and drug research and development will become more extensive and mature. It can not only fully release the application value of bioactive substances, but also promote the diversified value transformation of marine biological resources, providing strong support for the high-quality development of related industries.
References
InvivoChem. XEP-018 | NaV1.4 channel inhibitor | CAS 936616-33-0 [R]. United States: InvivoChem, 2023
PMC. Neuroprotective and cardioprotective conopeptides: An emerging class of drug leads[J]. Marine Drugs, 2010, 8(7):2878-2898.
Biblio. Gene expression, purification, and functional characterization of recombinant conotoxin μ-TIIIA and TIIIAlaMut[J]. Journal of Cosmetic Dermatology, 2023, 22(8):2156-2165.
MDPI. μ-Conotoxins Modulating Sodium Currents in Pain Perception and Transmission: A Therapeutic Potential[J]. Marine Drugs, 2017, 15(8):295.
PMC. μ-Conotoxins as Leads in the Development of New Analgesics[J]. Molecules, 2010, 15(4):2825-2848.
Hot Tags: mu-conotoxin, China mu-conotoxin manufacturers, suppliers, Botulinum Toxin Injection 100iu, Nad Capsule, Nad Peptide Injection, Nad Tablet, BPC 157 Peptide Cream, BPC 157 Peptide Capsules
